Metagenomi Therapeutics
56 hedge funds and large institutions have $11M invested in Metagenomi Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
2.04% more ownership
Funds ownership: 15.99% → 18.02% (+2%)
3% less funds holding
Funds holding: 58 → 56 (-2)
23% less capital invested
Capital invested by funds: $14.2M → $11M (-$3.21M)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$999K |
| 2 |
Jane Street
New York
|
+$726K |
| 3 |
Two Sigma Investments
New York
|
+$506K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$433K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$386K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$393K |
| 2 |
Walleye Capital
New York
|
-$169K |
| 3 |
Millennium Management
New York
|
-$163K |
| 4 |
JP Morgan Chase
New York
|
-$132K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$81K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $68 | -$40.5K | -18,724 | -100% |
|
52
Optiver Holding
Amsterdam,
Netherlands
| $29 | – | – | – |
|
|
AAP
53
Arax Advisory Partners
Denver,
Colorado
| $18 | -$41 | -19 | -63% |
|
54
Barclays
London,
United Kingdom
| $5 | – | – | – |
|
|
55
Walleye Capital
New York
| – | -$169K | -71,266 | Closed |
|
|
56
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$81K | -34,169 | Closed |
|
|
TCM
57
Tang Capital Management
San Diego,
California
| – | -$66.4K | -28,008 | Closed |
|
|
MG
58
Marex Group
London,
| – | -$34.5K | -15,000 | Closed |
|
|
GAA
59
Green Alpha Advisors
Niwot,
Colorado
| – | -$33.8K | -14,252 | Closed |
|
60
Citigroup
New York
| – | -$7.85K | -3,314 | Closed |
|
|
PWA
61
Physician Wealth Advisors
Midvale,
Utah
| – | -$1.45K | -610 | Closed |
|
62
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.28K | -592 | -96% |
|
|
PS
63
Principal Securities
Des Moines,
Iowa
| – | -$1.29K | -544 | Closed |
|
|
RWM
64
Rialto Wealth Management
Syracuse,
New York
| – | -$723 | -305 | Closed |
|
65
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$2 | -1 | -3% |
|
MGX Hedge Fund Activity: Q4 2025 in Review
56 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q4 2025, worth a combined $11M — down 23% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MGX positions and 9 closed out — a net gain of 2 holders — while 13 added to existing stakes and 18 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $999K. The largest seller was Morgan Stanley, cutting an estimated $393K.
- 56 institutional investors held Metagenomi Therapeutics (MGX) as of Q4 2025, down from 58 in Q3 2025.
- Funds reported $11M of Metagenomi Therapeutics stock for Q4 2025, down 23% quarter-over-quarter.
- 11 funds opened new Metagenomi Therapeutics positions in Q4 2025 and 9 closed out, a net change of +2 holders.
- The largest Metagenomi Therapeutics buyer in Q4 2025 was Renaissance Technologies, an estimated $999K added.
- The largest Metagenomi Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $393K sold.
Based on aggregated 13F filings for Q4 2025.